KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2016 - 2025)

Emergent BioSolutions has reported Asset Writedowns and Impairment over the past 12 years, most recently at $12.2 million for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $12.2 million; the TTM value through Dec 2025 reached $12.2 million, down 55.15%, while the annual FY2025 figure was $12.2 million, 55.15% down from the prior year.
Asset Writedowns and Impairment for Q4 2025 was $12.2 million at Emergent BioSolutions, down from $27.2 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $306.7 million in Q2 2023 and troughed at $12.2 million in Q4 2025.
A 3-year average of $115.4 million and a median of $27.2 million in 2024 define the central range for Asset Writedowns and Impairment.
On a YoY basis, Asset Writedowns and Impairment climbed as much as 91.13% in 2024 and fell as far as 91.13% in 2024.
Year by year, Asset Writedowns and Impairment stood at $306.7 million in 2023, then crashed by 91.13% to $27.2 million in 2024, then crashed by 55.15% to $12.2 million in 2025.
Business Quant data shows Asset Writedowns and Impairment for EBS at $12.2 million in Q4 2025, $27.2 million in Q2 2024, and $306.7 million in Q2 2023.